A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia

Clinical Therapeutics

Volumn 29, Issue 6, 2007, Pages 1107-1115

  Jeffres, Meghan N ^a   Isakow, Warren ^b   Doherty, Joshua A ^c   Micek, Scott T ^a   Kollef, Marin H ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Medical Informatics   (United States)

Author keywords

methicillin resistance; pneumonia; renal toxicity; Staphylococcus aureus

Indexed keywords

CREATININE; VANCOMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DATA BASE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; NONHUMAN; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CREATININE; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; RETROSPECTIVE STUDIES; RISK FACTORS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 34547686271     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.06.014     Document Type: Article

References (29)

1. American Thoracic Society and the Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
2. Lamer C., de Beco V., Soler P., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 37 (1993) 281-286
3. Cruciani M., Gatti G., Lazzarini L., et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 38 (1996) 865-869
4. DeRyke C., Lodise Jr. T., Rybak M., and McKinnon P. Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest 128 (2005) 1414-1422
5. Jeffres M., Isakow W., Doherty J., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices. Chest 130 (2006) 947-955
6. Hidayat L., Hsu D., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 166 (2006) 2138-2144
7. Geraci J., Heilman F., Nichols D., and Wellman W. Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis: Preliminary report. Mayo Clin Proc 33 (1958) 172-181
8. Kralovicova K., Spanik S., Halko J., et al. Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?. J Chemother 9 (1997) 420-426
9. Zimmermann A., Katona B., and Plaisance K. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 15 (1995) 85-91
10. Cimino M., Rotstein C., Slaughter R., and Emrich L. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 83 (1987) 1091-1097
11. Rybak M., Albrecht L., Boike S., and Chandrasekar P. Nephrotoxicity of vancomycin, alone and with aminoglycoside. J Antimicrob Chemother 25 (1990) 679-687
12. Downs N., Neihart R., Dolezal J., and Hodges G. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 149 (1989) 1777-1781
13. Elting L., Rubenstein E., Kurtin D., et al. Mississippi mud in the 1990s: Risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 83 (1998) 2597-2607
14. Merten G., Burgess W., Gray L., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 291 (2004) 2328-2334
15. Moellering Jr. R., Krogstad D., and Greenblatt D. Vancomycin therapy in patients with impaired renal function: A nomogram for dosage. Ann Intern Med 94 (1981) 343-346
16. Concato J., Feinstein A., and Holford T. The risk of determining risk with multivariable models. Ann Intern Med 118 (1993) 201-210
17. Farber B., and Moellering Jr. R. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23 (1983) 138-141
18. Bergman M., Glew R., and Ebert T. Acute interstitial nephritis associated with vancomycin therapy. Arch Intern Med 148 (1988) 2139-2140
19. Levine D. Vancomycin: A history. Clin Infect Dis 42 Suppl 1 (2006) S5-S12
20. Goetz M., and Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination [published correction appears in J Antimicrob Chemother. 1993;32:925]. J Antimicrob Chemother 32 (1993) 325-334
21. Lowy F. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 111 (2003) 1265-1273
22. Kirst H., Thompson D., and Nicas T. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 42 (1998) 1303-1304
23. Sakoulas G., Moise-Broder P., Schentag J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
24. Sakoulas G., Moellering Jr. R., and Eliopoulos G. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 42 Suppl 1 (2006) S40-S50
25. Rello J., Sole-Violan J., Sa-Borges M., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 33 (2005) 1983-1987
26. Kollef M., Rello J., Cammarata S., et al. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 30 (2004) 388-394
27. Livermore D. Tigecycline: What is it, and where should it be used?. J Antimicrob Chemother 56 (2005) 611-614
28. Schmitt-Hoffmann A., Roos B., Schleimer M., et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48 (2004) 2570-2575
29. Ellis M., and Lewis II J. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 18 (2005) 496-501